Shu Cheng

机构：Shanghai Jiao Tong University, Ruijin Hospital, Shanghai Institute of Hematology · ORCID：0000-0001-7077-4165

发表论文 65 篇 · 总被引 1138 次 · h-index 19

代表论文

• A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia (2021 · Clinical Cancer Research · 被引 40)
• Enhanced lipid metabolism confers the immunosuppressive tumor microenvironment in CD5-positive non-MYC/BCL2 double expressor lymphoma (2022 · Frontiers in Oncology · 被引 27)
• KMT2D mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-induced regulatory T cell trafficking via FBXW7-NOTCH-MYC/TGF-β1 axis (2024 · International Journal of Biological Sciences · 被引 17)
• Anti-metabolic agent pegaspargase plus PD-1 antibody sintilimab for first-line treatment in advanced natural killer T cell lymphoma (2024 · Signal Transduction and Targeted Therapy · 被引 15)
• Chromosome-Level Genome Assembly Provides New Insights into Genome Evolution and Tuberous Root Formation of Potentilla anserina (2021 · Genes · 被引 13)
• The Prognostic Significance of CD79B Mutation in Diffuse Large B-Cell Lymphoma: A Meta-analysis and Systematic Literature Review (2022 · Clinical Lymphoma Myeloma & Leukemia · 被引 11)